48 Søgeresultatnew orleans

LEO Pharma

LEO Pharma Presents Late-Breaking Results from the Phase 2a Mechanism of Action Trial of Temtokibart and Dupilumab in Moderate-to-Severe Atopic Dermatitis at the 2024 EADV Annual Meeting26.9.2024 14:30:00 CEST | LEO Pharma | Pressemeddelelse

Results presented at the Late Breaker Session on September 26th at the European Dermatology Congress, European Academy of Dermatology & Venereology (EADV) 2024, showed that the investigational interleukin 22 receptor, alpha 1 (IL-22RA1) inhibitor temtokibart induced fast (Week 1) molecular responses(1) Markers of skin hydration (natural moisturizing factors) 2-pyrrolidone-5-carboxylic acid (PCA) and urocanic acid (UCA) were significantly improved from baseline at Week 1 in the temtokibart group (p<0.0001)(1) Both temtokibart and dupilumab led to comparable changes in eczema area and severity index (EASI) and itch numerical rating scale (NRS) at Week 16(1)
LEO Pharma

LEO Pharma Unveils Most Extensive EADV Program To Date with 5 Late Breaking Abstracts and 23 Posters Sharing Clinical and Real-World Data25.9.2024 10:00:00 CEST | LEO Pharma | Pressemeddelelse

LEO Pharma will demonstrate true leadership in medical dermatology by presenting one of its largest ever scientific programs to date at this year’s EADV congress, with 5 late-breaking presentations and 23 scientific posters in total.(1-28) New late-breaking Anzupgo® (delgocitinib) cream data will include the full results of the Phase 3 head-to-head DELTA FORCE trial, as well as a wide range of associated clinical and real-world findings on delgocitinib cream and moderate to severe chronic hand eczema (CHE).(1-6) Additional late-breaking data includes a presentation of Adtralza® (tralokinumab)/Adbry ® (tralokinumab-ldrm) interim data from the real-world TRACE study on the effectiveness of Adtralza/Adbry in adults with moderate to severe head and neck atopic dermatitis (AD).(27) Finally, a late-breaking presentation will discuss the first randomized trial comparing clinical and molecular effects of temtokibart and dupilumab in moderate to severe AD.(28)
Roots & Jazz

Roots & Jazz flytter til den Røde Plads28.5.2024 08:53:00 CEST | Roots & Jazz | Pressemeddelelse

En af Copenhagen Jazzfestivals største scener får nyt hjem i 2024 med 10 dages musik i topklasse. I mere end 10 år har Roots & Jazz præget Nørrebro under Copenhagen Jazzfestival, og har vundet både publikums hjerter og international anerkendelse som en af de mest populære scener under festivalen. Festivalen er groet ud af rammerne på Balders Plads og præsenterer i år 29 koncerter på Den Røde Plads 5.-14. juli. Og der bliver meget at glæde sig til…

JACOB COLLIER OFFENTLIGGØR KONCERTER I UK OG EUROPA PÅ SIN DJESSE VOL. 4 WORLD TOUR 2024 INKL. SHOW I FORUM BLACK BOX24.11.2023 11:00:00 CET | Live Nation Denmark ApS | Pressemeddelelse

Den femdobbelte GRAMMY-vindende singer-songwriter, multiinstrumentalist og producer offentliggør sin største Europa-tour til dato, hvor han bl.a. kommer til at optræde i Forum Black Box, samt andre ikoniske koncertsteder som The O2 i London, Wizink Center i Madrid og mere end 20 andre byer på kontinentet. Billetsalget starter fredag 1. december kl. 10:00 på JacobCollier.com/Tour
LEO Pharma

LEO Pharma to Reveal New Findings in Moderate to Severe Atopic Dermatitis (AD) and Chronic Hand Eczema (CHE) at the 2023 EADV Congress12.10.2023 11:00:00 CEST | LEO Pharma | Pressemeddelelse

New Adtralza® (tralokinumab) data examines the long-term safety and efficacy of the drug for the treatment of moderate to severe AD, as well as its real-world clinical positioning.1,2,3 Delgocitinib cream presentations include new data from the DELTA 2 clinical trials, which assessed the safety and efficacy of the topical treatment for moderate to severe CHE.4,5 Phase 2a trial results assessing the efficacy and safety of temtokibart (LEO 138559), LEO Pharma's IL-22RA1 antibody, will also be presented at the conference.6
LEO Pharma

Temtokibart achieves First Subject First Treatment (FSFT) milestone in Phase 2b trial11.10.2023 14:00:00 CEST | LEO Pharma | Pressemeddelelse

Temtokibart, LEO Pharma's investigational IL-22RA1 antibody (formerly labelled as LEO 138559), reaches latest trial milestone. Phase 2b initiation follows the completion of the Phase 2a trial, the results of which were presented at the American Academy of Dermatology (AAD) Annual Meeting earlier this year.1 The trial will be overseen by a steering committee featuring a selection of clinical experts.
LEO Pharma

LEO Pharma Presents Late-Breaking Positive Phase 3 Results of Delgocitinib Cream in Adults with Moderate to Severe Chronic Hand Eczema (CHE) at AAD 202318.3.2023 17:40:00 CET | LEO Pharma | Press release

• Results demonstrated that delgocitinib cream provided statistically significant improvements in primary and all key secondary endpoints, which included both clinician-assessed and patient-reported efficacy outcomes compared to cream vehicle.1 • Delgocitinib cream showed a statistically significant treatment effect compared to cream vehicle as early as four weeks after initiation of treatment.1
Live Nation Denmark ApS

Den Grammy-prisvindende R&B-stjerne, Lucky Daye, kommer til København 18. september 2022.30.5.2022 09:00:00 CEST | Live Nation Denmark ApS | Pressemeddelelse

LUCKY DAYE: CANDYDRIP TOUR 2022 DR KONCERTHUSET, STUDIE 2 18. SEPTEMBER 2022 Den Grammy-prisvindende R&B-stjerne, Lucky Daye, kommer til København 18. september 2022. Lucky Daye opdagede sin kærlighed til musik og naturlige gave til sang og sangskrivning tidligt i livet i sin hjemby, New Orleans. Fordrevet af orkanen Katrinas ødelæggelser flyttede Lucky til Atlanta for en kort periode og flyttede så til sidst til Los Angeles for at forfølge sine musikdrømme. Efter at have mødt producer D'Mile og arbejdet med ham på sit debutalbum ’’Painted’’, indså Lucky fuldt ud sin stemme og potentiale. Hans ubestridelige talent som vokalist tog form og landede en pladekontrakt hos Keep Cool label i samarbejde med RCA Records. For nyligt vandt Lucky Daye en Grammy Award for bedste progressive R&B-album for sin EP Table for Two fra 2021. Hans seneste udgivelse er ’’Candydrip’’ med hitsinglen "Over", som han fremførte på The Tonight Show med Jimmy Fallon. Albummet debuterede som #5 på Billboard Top R&B
  • 1
  • 2
  • 3
  • Sidste
  • >>
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye